Marker Therapeutics (MRKR) Return on Capital Employed (2011 - 2026)
Marker Therapeutics (MRKR) posted quarterly Return on Capital Employed of 84.53% for Q1 2026, down 499.0% year-over-year from 21.19% in Q1 2025, and down 15.75% quarter-over-quarter from 73.03% in Q4 2025.
Marker Therapeutics (MRKR) Return on Capital Employed (2011 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has reported Return on Capital Employed for 16 consecutive years, with 84.53% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed fell 499.0% year-over-year to 84.53%; the TTM figure through Mar 2026 stood at 84.53% (down 499.0% YoY), while the FY2025 annual figure was 70.54%, down 153.0% from the prior year.
- Return on Capital Employed retreated to 84.53% in Q1 2026 per MRKR's latest filing, from 73.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 71.0% in Q1 2023 and bottomed at 133.41% in Q2 2025.
- Historically, Return on Capital Employed has averaged 90.68% across 5 years, with a median of 85.51% in 2024.
- Annual changes were most pronounced in 2024 — Return on Capital Employed tumbled 4834 bps — and 2025, when it jumped 2808 bps.
- Marker Therapeutics' Return on Capital Employed stood at 79.8% in 2022, then fell by 20 bps to 95.73% in 2023, then increased by 11 bps to 85.51% in 2024, then climbed by 15 bps to 73.03% in 2025, then retreated by 16 bps to 84.53% in 2026.
- Business Quant data shows MRKR's Return on Capital Employed at 84.53% in Q1 2026, 73.03% in Q4 2025, and 102.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Marker Therapeutics | 23.95 Mn | 12.02 Mn | - | -78.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -84.53% |
| Dec 31, 2025 | -73.03% |
| Sep 30, 2025 | -102.09% |
| Jun 30, 2025 | -133.41% |
| Mar 31, 2025 | -79.54% |
| Dec 31, 2024 | -85.51% |
| Sep 30, 2024 | -130.17% |
| Jun 30, 2024 | -100.77% |
| Mar 31, 2024 | -96.35% |
| Dec 31, 2023 | -95.73% |
| Sep 30, 2023 | -81.83% |
| Jun 30, 2023 | -78.58% |
| Mar 31, 2023 | -71.00% |
| Dec 31, 2022 | -79.80% |
| Sep 30, 2022 | -86.52% |
| Jun 30, 2022 | -86.77% |
| Mar 31, 2022 | -75.93% |
| Dec 31, 2021 | -69.09% |
| Sep 30, 2021 | -56.23% |
| Jun 30, 2021 | -45.17% |